Use of Eribulin mesylate as second-line therapy in elderly patients with HER/2 negative metastatic breast cancer (MBC): efficacy, tolerability and Quality of Life.

De Luca, R; Alù, M; Genova, G; Grassadonia, A; Cicero, G

De Luca, R; Alù, M; Genova, G; Grassadonia, A; Cicero, G.

Affiliation

De Luca R; Department of Surgical, Oncological and Oral Sciences, Section of Medical Oncology, University of Palermo, Palermo, Italy. giuseppe.cicero@unipa.it.

Eur Rev Med Pharmacol Sci ; 24(24): 12727-12734, 2020 12.

Article in En | MEDLINE | ID: mdl-33378020

Subject(s)

Antineoplastic Agents/therapeutic use; Breast Neoplasms/drug therapy; Furans/therapeutic use; Ketones/therapeutic use; Aged; Aged, 80 and over; Breast Neoplasms/pathology; Drug Tolerance; Female; Humans; Quality of Life

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Furans / Ketones / Antineoplastic Agents Type of study: Observational_studies Aspects: Patient_preference Limits: Aged / Aged80 / Female / Humans Language: En Journal: Eur Rev Med Pharmacol Sci Journal subject: FARMACOLOGIA / TOXICOLOGIA Year: 2020 Document type: Article Affiliation country: Italy Country of publication: Italy

Fulltext

Add to My VHL

XML

PubMed Links

Search on Google